Lundbeck’s drug portfolio faces patent expirations but shows growth potential. Find out why HLBBF stock could see upside with ...

Approximately $50.0 million of net revenue from sales of LUMRYZ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 patients ...

Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and ...

LUMRYZ, is an extended-release sodium oxybate medication approved by the FDA on May 1, 2023, as the first and only once-at-bedtime treatment for cataplexy or excessive daytime sleepiness (EDS) in ...

Lifecore Biomedical, Inc. beats earnings expectations. Reported EPS is $-0.25, expectations were $-0.27. Operator: Good ...

It is a newer concept for pharma ... for sales, marketing and patient communication materials, in print or digital form. It might encompass elements such as headlines, body copy, images, calls ...

"Sectors like chemicals, defence, renewables and electronics manufacturing services are poised for significant growth despite high valuations, led by scalability in business, in 2025," Satish Menon, ...

Healthcare professional (HCP) engagement experienced significant shifts during the acute phase of the pandemic, as COVID-19 forced a rethink of traditional pharmaceutical sales and marketing ...

Macy’s Inc. has appointed Robert Chavez, former Hermes Americas CEO, to the board. He faces challenges influencing strategy ...

Alcoholic drinks like beer and wine should carry warnings of their links to cancer, the US’s top doctor said, citing a lack ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...